Moderna partners with Tempus on cancer therapy
The multi-year agreement supports commercial preparation for intismeran autogene in melanoma.
Moderna and Merck announced an expanded, multi-year collaboration with Tempus on October 7, 2026. The agreement aims to support the potential commercialization of intismeran autogene, an investigational individualized neoantigen therapy jointly developed by Moderna and Merck.
The candidate, also known as V940 or mRNA-4157, is being evaluated alongside Merck's anti-PD-1 drug Keytruda in patients with completely resected stage IIB-IV melanoma and other forms of cancer. The expanded agreement builds on initial joint efforts started last year.
Under the partnership, Tempus will manage the collection and transfer of tumor tissue and blood samples for next-generation sequencing. Subject to regulatory approvals, Tempus will also provide sequencing services to support therapy design and manufacturing. The companies did not disclose financial terms.
Bringing an individualized therapy like intismeran autogene from clinical development toward potential commercialization requires a seamless, highly reliable diagnostic network. Working with Tempus allows us to leverage their commercial footprint and advanced sequencing capabilities as we work to deliver individualized neoantigen therapies to patients at scale.
Newsletter
Markets in your inbox, weekly
LATAM-focused analysis, investing ideas, and the week in finance.
Keep reading
